BG106193A - Използване на антитела срещу cd20 за лечение на заболявания при трансплантации - Google Patents

Използване на антитела срещу cd20 за лечение на заболявания при трансплантации Download PDF

Info

Publication number
BG106193A
BG106193A BG106193A BG10619301A BG106193A BG 106193 A BG106193 A BG 106193A BG 106193 A BG106193 A BG 106193A BG 10619301 A BG10619301 A BG 10619301A BG 106193 A BG106193 A BG 106193A
Authority
BG
Bulgaria
Prior art keywords
lymphocytes
human
antigen
cells
antibodies against
Prior art date
Application number
BG106193A
Other languages
Bulgarian (bg)
English (en)
Inventor
Josee Golay
Martino Introna
Alessandro Rambaldi
Andrea Biondi
Original Assignee
Consiglio Nazionale Delle Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche filed Critical Consiglio Nazionale Delle Ricerche
Publication of BG106193A publication Critical patent/BG106193A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BG106193A 1999-06-11 2001-12-07 Използване на антитела срещу cd20 за лечение на заболявания при трансплантации BG106193A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (1)

Publication Number Publication Date
BG106193A true BG106193A (bg) 2002-08-30

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106193A BG106193A (bg) 1999-06-11 2001-12-07 Използване на антитела срещу cd20 за лечение на заболявания при трансплантации

Country Status (26)

Country Link
US (1) US20070014785A1 (sk)
EP (1) EP1185299B1 (sk)
JP (1) JP2003501482A (sk)
KR (1) KR20020026455A (sk)
CN (1) CN1253208C (sk)
AU (1) AU774206B2 (sk)
BG (1) BG106193A (sk)
CA (1) CA2376288A1 (sk)
CZ (1) CZ20014450A3 (sk)
DE (1) DE60033030T2 (sk)
DK (1) DK1185299T3 (sk)
EE (1) EE200100667A (sk)
ES (1) ES2278616T3 (sk)
HK (1) HK1043549B (sk)
HU (1) HUP0201600A3 (sk)
IL (1) IL146934A0 (sk)
IS (1) IS6195A (sk)
IT (1) ITMI991299A1 (sk)
NO (1) NO20016035L (sk)
NZ (1) NZ515992A (sk)
PL (1) PL352860A1 (sk)
PT (1) PT1185299E (sk)
SK (1) SK18132001A3 (sk)
TR (1) TR200103581T2 (sk)
WO (1) WO2000076542A1 (sk)
ZA (1) ZA200110004B (sk)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1572744B1 (en) * 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
NZ568403A (en) 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
PT2272868E (pt) 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
CA2560751A1 (en) * 2004-03-22 2005-10-06 The Ohio State University Research Foundation Methods for transfecting natural killer cells
WO2005117978A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Method for treating multiple sclerosis
EP2213683B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant Fc regions
EP1902320B1 (en) 2005-05-20 2010-03-10 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
EP1919505A2 (en) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
US20100183586A1 (en) * 2007-06-22 2010-07-22 Tsukasa Hori Method for detection or treatment of graft versus host disease
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
CA2695199C (en) 2007-07-31 2016-07-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
KR20210054528A (ko) 2018-08-31 2021-05-13 리제너론 파아마슈티컬스, 인크. Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1997045142A1 (en) * 1996-05-31 1997-12-04 Genetic Therapy, Inc. Prevention of graft-versus-host disease with t-cells including polynucleotides encoding negative selective markers
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
SK18132001A3 (sk) 2002-05-09
PL352860A1 (en) 2003-09-08
EP1185299A1 (en) 2002-03-13
TR200103581T2 (tr) 2002-08-21
ITMI991299A0 (it) 1999-06-11
US20070014785A1 (en) 2007-01-18
CA2376288A1 (en) 2000-12-21
DK1185299T3 (da) 2007-05-21
AU5530300A (en) 2001-01-02
CN1253208C (zh) 2006-04-26
IL146934A0 (en) 2002-08-14
HUP0201600A3 (en) 2005-04-28
PT1185299E (pt) 2007-03-30
WO2000076542A1 (en) 2000-12-21
CZ20014450A3 (cs) 2002-04-17
HUP0201600A2 (en) 2002-08-28
KR20020026455A (ko) 2002-04-10
IS6195A (is) 2001-12-10
NO20016035D0 (no) 2001-12-10
NO20016035L (no) 2002-02-11
DE60033030D1 (de) 2007-03-08
CN1355712A (zh) 2002-06-26
ZA200110004B (en) 2003-02-26
JP2003501482A (ja) 2003-01-14
NZ515992A (en) 2004-01-30
AU774206B2 (en) 2004-06-17
ES2278616T3 (es) 2007-08-16
EP1185299B1 (en) 2007-01-17
ITMI991299A1 (it) 2000-12-11
HK1043549A1 (en) 2002-09-20
EE200100667A (et) 2003-02-17
HK1043549B (zh) 2006-09-01
DE60033030T2 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
BG106193A (bg) Използване на антитела срещу cd20 за лечение на заболявания при трансплантации
Rosenzweig et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells
Serafini et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease
Donahue et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.
US5470730A (en) Method for producing TH -independent cytotoxic T lymphocytes
JP2001505043A (ja) 遺伝子導入
Berger et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model
JP2021502094A (ja) 閉鎖系極低温容器
EP1188825A1 (en) T cell receptor transfer into a candidate effector cell or a precursor thereof
Verhoeyen et al. Lentiviral vector gene transfer into human T cells
Kang et al. Induction of central deletional T cell tolerance by gene therapy
Burt et al. Herpes simplex thymidine kinase gene–transduced donor lymphocyte infusions
Hagani et al. Activation conditions determine susceptibility of murine primary T‐lymphocytes to retroviral infection
Clay et al. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer
Introna et al. Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells
JP2002501375A (ja) ワクチン評価のための動物モデル
Donahue et al. High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34+ cells
Maslennikova et al. Engineering T-cell resistance to HIV-1 infection via knock-in of peptides from the heptad repeat 2 domain of gp41
Engel et al. Stem cell directed gene therapy
Poznansky et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
CN114269356A (zh) 诱导细胞免疫和体液免疫的基于同种异体t细胞的hiv疫苗
JP2004523202A (ja) 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用
EP0904786B1 (en) Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction
Schejtman Borisonik Lentiviral gene therapy for p47-deficient Chronic Granulomatous disease
Naranjo-Gomez et al. Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy. Vaccines 2021, 9, 137